Mr. Ford is President of Leadiant Biosciences Ltd. Mr. Ford has more than 30 years of experience in the pharmaceutical industry. He spent the majority of that time with G.D. Searle where he served in a variety of positions including European Finance Director, General Manager of UK Operations, Vice President of Middle East/African Region including subsidiaries in Pakistan and India, Vice President Corporate Licensing/Business Development in the USA, and President of The European Region with a turnover of $800+ million, 18 operating units and 2,500 people. He was a member of the Searle Worldwide Executive Management Team, a $2.5 billion corporation.
His experience spans involvement in strategic alliances, acquisitions, joint ventures, in-licensing, co- marketing/co-development arrangements, product evaluations and strategic and operational reviews.
Dr. Marco Brughera
Chief Executive Officer and Global Head, Rare Disease
Dr. Brughera is Chief Executive Officer and Global Head, Rare Disease of Leadiant Biosciences S.p.A. Dr. Brughera has extensive experience in R&D, business development and general management particularly in the oncology and rare disease areas across several global pharmaceutical, rare disease and biotech companies.
From January 2011 through October 2012, Dr. Brughera was Corporate Research and Development Managing Director of the Sigma-Tau Group. From 2004 to 2010, he served as the Vice President of Preclinical Development at Nerviano Medical Sciences S.r.l. (“NMS Group”), a pharmaceutical oncology- focused integrated R&D company. He also served as the Managing Director at Accelera S.r.l., an independent contract research organization affiliated with the NMS Group. From 1999 to 2004, Dr. Brughera held several senior level positions in the areas of Discovery and Development with Pharmacia Corporation and Pfizer, Inc. Prior to 1999, he held various positions at Pharmacia & Upjohn, Kabi- Pharmacia and Farmitalia Carlo Erba.
Dr. Brughera earned his degree in Veterinary Medicine from the University of Milan and is a European Registered Toxicologist. He attended Management Courses at Thunderbird American Graduate Business School at Arizona State University and MIT. He was EFPIA deputy topic leader for the ICH review of the Oncology Therapeutic Guidance. Publication record includes more 60 publications/communications.
He is currently Board Member of the following publically traded companies: Soligenix, Inc., Fennec Pharmaceuticals, Inc., and Lee’s Pharmaceutical Holdings Ltd. He was Board Member at Gentium from December 2011 to January 2014.
Board of Directors Member
Mr. Dini was a strategy and organisation consultant at PricewaterhouseCoopers handling transformational change and organisational design of large companies in many fields like Telecoms, Healthcare, Public Utilities and Government.
Mr. Dini has extensive experience in Pfizer Italy covering a wide range of roles within Marketing and Sales, Strategic Business Planning, Brand Marketing, Customer Marketing and Sales Intelligence and Effectiveness. He earned his degree in economics at Libera Università Internazionale degli Studi Sociali Guido Carli in Rome.
Dr. Raffaele Sanguigni
Board of Directors Member
Dr. Sanguigni has more than 30 years of experience in key, strategic roles in the pharmaceutical industry. Until February 2016, he served as General Manager of Sigma-Tau Group leading the entire operations of the company.
Within the Sigma-Tau Group he held several top management positions including Chief Executive Offficer of Avantgarde S.p.A., Chief Executive Officer of Biosint S.p.A., President of Biofutura S.p.A and Chairman of several European Affiliates.
Dr. Sanguigni has advanced knowledge and experience in production, logistics, co-marketing and licensing, commercial policies, sales, regulatory, governance and partnering. He graduated with a degree in Agricultural Sciences from the Perugia University.